Muscarine receptor activation in the substantia gelatinosa of the spinal trigeminal nucleus of the guinea pig.
1. Intracellular recordings were made from slices of guinea pig spinal trigeminal nucleus pars caudalis (SG). 2. Muscarine [0.3-30 microM; half maximally effective concentration (EC50) = 2.9 microM] hyperpolarized 61% of SG neurons. The effect was mimicked by carbachol (0.3-30 microM; EC50 = 3.9 microM) and antagonized by pirenzepine (1 microM). Thirty-four percent of the neurons were depolarized by muscarine and carbachol (1-30 microM: EC50 = 5.7 microM), and the effect was antagonized by pirenzepine (100 nM). 3. In approximately 80% of recordings, muscarine (10-30 microM) evoked repetitive spontaneous inhibitory postsynaptic potentials (IPSPs) that were sensitive to bicuculline (10 microM). 4. Muscarine (1-30 microM; EC50 = 3 microM) decreased the amplitude of the majority of evoked excitatory postsynaptic potentials (EPSPs), and the effect was mimicked by carbachol and antagonized by pirenzepine (100 nM). 5. These results indicate that there are at least three mechanisms by which muscarine inhibits SG neurons: 1) hyperpolarization through activation of non-M1 receptors; 2) activation of gamma-amino-butyric acid-containing interneurons that mediate IPSPs in a subset of neurons; and 3) a decrease in evoked EPSP amplitude. Muscarine can also activate SG neurons via interaction with an M1-type receptor.
Travagli
R A
RA
Department of Physiology, West Virginia University School of Medicine, Morgantown, 26506-9229, USA.
D000818:Animals; D002217:Carbachol / Q000494:pharmacology; D006224:Cricetinae; D005071:Evoked Potentials / Q000187:drug effects; D066298:In Vitro Techniques; D008297:Male; D008564:Membrane Potentials / Q000187:drug effects; D009116:Muscarine / Q000494:pharmacology; D018721:Muscarinic Agonists / Q000494:pharmacology*; D018727:Muscarinic Antagonists / Q000494:pharmacology*; D009474:Neurons / Q000187:drug effects; D018408:Patch-Clamp Techniques; D010890:Pirenzepine / Q000494:pharmacology; D017470:Receptors, Glutamate / Q000187:drug effects; D013376:Substantia Gelatinosa / Q000187:drug effects*; D014279:Trigeminal Nucleus, Spinal / Q000166:cytology / Q000187:drug effects*
D018721:Muscarinic Agonists; D018727:Muscarinic Antagonists; D017470:Receptors, Glutamate; D010890:Pirenzepine; D009116:Muscarine; D002217:Carbachol